Continuative statin therapy after percutaneous coronary intervention improves outcome in coronary bypass surgery: A propensity score analysis of 2501 patients  by Mannacio, Vito et al.
Acquired Cardiovascular Disease Mannacio et al
A
C
DContinuative statin therapy after percutaneous coronary intervention
improves outcome in coronary bypass surgery: A propensity score
analysis of 2501 patientsVito Mannacio, MD,a Pascal Meier, MD,b,c Anita Antignano, MD,d Michele Mottola, MD,a
Luigi Di Tommaso, MD,a Francesco Musumeci, MD,e and Carlo Vosa, MDaFrom th
Italy;
New
Unite
Pausi
Osped
Disclosu
Receive
public
Address
(E-ma
0022-52
Copyrig
http://dx
1876Objectives: A history of percutaneous coronary intervention increases the risk of death and complications of
coronary artery bypass grafting. This retrospective multicenter study evaluated the impact of continuative use
of statin on postoperative outcomes when subsequent elective coronary artery bypass grafting is required after
percutaneous coronary intervention.
Methods: Among 14,575 patients who underwent isolated first-time coronary artery bypass grafting between
January 2000 and December 2010, 2501 who had previous percutaneous coronary intervention with stenting
and fulfilled inclusion criteria were enrolled. Continuative statin therapy was used in 1528 patients and not used
in 973 patients. Logistic multiple regression and propensity score analyses were used to assess the risk-adjusted
impact of statin therapy on in-hospital mortality and major adverse cardiac events. The Cox proportional hazards
model was constructed to assess the effect of continuative statin therapy on 24-month outcome.
Results: At multivariate analysis, age more than 70 years, 3-vessel or 2-vessel plus left main coronary disease,
multivessel percutaneous coronary intervention, ejection fraction 0.40 or less, diabetes mellitus, and logistic
European System for Cardiac Operative Risk Evaluation 5 or greater were independent predictors of hospital
mortality and major adverse cardiac events. After propensity score matching, conditional logistic regression
analysis demonstrated that continuative statin therapy before coronary artery bypass grafting reduced the risk
for hospital and 2-year mortality (odds ratio [OR], 0.27; 95% confidence interval [CI], 0.12-0. 57; P ¼ .004
and OR, 0.6; 95% CI, 0.36-0.96; P ¼ .04, respectively) and major adverse cardiac events (OR, 0.31; 95%
CI, 0.18-0.78; P ¼ .003 and OR, 0.5; 95% CI, 0.34-0.76; P ¼ .006, respectively).
Conclusions: Long-term statin treatment after percutaneous coronary intervention improves early and midterm
outcome when surgical revascularization will be required. (J Thorac Cardiovasc Surg 2014;148:1876-83)See related commentary on pages 1884-6.Recent studies indicate that 10% to 30% of the patients
treated by percutaneous coronary intervention (PCI) for
multivessel coronary disease require repeated coronary
revascularization because of symptom recurrence and
restenosis within 2 to 4 years after primary intervention.1,2
When a subsequent coronary artery bypass grafting
(CABG) is necessary, a history of PCI is associated with a
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The Journal of Thoracic and Cardiovascular Surin the setting of these high-risk patients, novel technical
and pharmacologic strategies are required.
Recent guidelines suggest antiplatelet therapy for
primary and secondary prevention before and after
implantation of stents or in surgical patients to improve
vein-graft patency after CABG.8-11 Furthermore, robust
evidence supports the early and aggressive therapy with
inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
reductase statins to reduce cardiovascular adverse events
and repeat revascularization procedures after PCI.12 In
patients undergoing CABG, statin therapy exerts multiple
pleiotropic effects associated with reduction of myocardial
damage and better surgical results.13-17 This overall efficacy
of statins is reflected in the latest American College of
Cardiology/American Heart Association guidelines.
However, the effect of statin on postoperative outcome of
patients with a history of PCI, subsequently referred to
CABG, has not been evaluated until now.
Because of the important clinical implications, this study
evaluated the impact of continuative statin treatment on early
and midterm cardiac mortality and nonfatal major adverse
cardiac events (MACE) in those patients who are finally
referred to elective CABG after previous PCI by stenting.gery c November 2014
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
MACE ¼ major adverse cardiac events
MI ¼ myocardial infarction
NO ¼ nitric oxide
OR ¼ odds ratio
PCI ¼ percutaneous coronary intervention
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The study was a retrospective multicenter cohort study designed
according to the STROBE statement. Among a total of 14,575 patients
who underwent first-time isolated CABG between January 2000 and
February 2010, 2051 consecutive patients previously treated by PCI by
stenting were evaluated. Additional cardiac procedures and urgent or
emergency CABG were exclusion criteria. Patients were classified
depending on whether they received (statin group) or did not receive
(no statin group) continuous treatment with any kind of statins during
the period between PCI and CABG surgery. Types of statin used and
the usual dosages were as follows: atorvastatin 20 to 40 mg/d, rosuvasta-
tin 10 to 20 mg/d, simvastatin 20 to 40 mg/d, pravastatin 20 to 40 mg/d,
and fluvastatin 20 to 40 mg/d. All patients with suspected low adherence
to statin therapy during the last 6 months before CABG were excluded.
Adherence to therapy was assessed by rates of prescription refills as
reported by Osterberg and Blaschke.18 We measured statin adherence
as the proportion of days covered. We defined patients as being
‘‘adherent’’ if the proportion of days covered was 80% or more. Change
from one statin to another was considered adherence with therapy. A total
of 1528 patients treated by continuative statin therapy were identified and
compared with 973 patients who did not receive continuative statin
treatment after PCI. In the statin group, the overall proportion of days
covered was 86.4%.
All patients underwent preoperative coronary angiography. Risk
stratification was assessed by the logistic European System for Cardiac
Operative Risk Evaluation. Low-density lipoprotein levels before the
operation were 120  28 mg/dL in the statin group and 159  39 mg/dL
in the no statin group (P< .001). The main demographic and clinical
characteristics of the patients are shown in Table 1.
Troponin I values, assessed preoperatively, and at 8 and 12 hours
after operation, and then on every postoperative day until hospital
discharge, were collected as markers of myocardial damage. The dose
of inotropic support, when required, was considered indicative of
postoperative outcome. To avoid bias due to the different duration of
follow-up, the last time point for postoperative evaluation was fixed
at 24 postoperative months in all patients.
The study protocol was approved by the ethics committee of the
University of Naples Federico II. All patients preliminarily granted
permission for the use of their medical records for research purposes;
thus, individual patient consent was waived for this study.
Perioperative Management
Patients receiving antiplatelet therapy before surgery were managed
in accordance with the 2011 American College of Cardiology
Foundation/American Heart Association Guideline for Coronary Artery
Bypass Graft Surgery.19 Standardized dual antiplatelet therapy was
started when chest tube drainage was less than 20 mL/h.9 Statins
were given 24 hours after surgery and continued over all follow-up
time in all patients.16The Journal of Thoracic and CarOutcome Measures and Definitions
The end points were (1) hospital mortality and major adverse cardiac
events (MACE) and (2) 2-year mortality and MACE.
Hospital mortality was defined as death within 30 days or at any time
after operation if the patient did not leave the hospital alive. MACE were
defined as a composite end point of nonfatal perioperative myocardial
infarction (MI), low output syndrome, significant cardiac arrhythmias,
and need for repeat surgical or percutaneous revascularization.
Perioperative acute MI was diagnosed when the criteria indicated by the
Joint European Society of Cardiology/American College of Cardiology
Foundation/American Heart Association/World Heart Federation Task
Force for the Universal Definition of Myocardial Infarction guidelines
were fulfilled.20 Troponin I leakagewithout electrocardiographic modifica-
tions, new loss of viable myocardium, and new regional wall motion
abnormality were considered as myocardial damage.16 Postoperative renal
disease was defined as serum creatinine 2.5 mg/dL or greater. Low output
syndrome was diagnosed as previously described.21 High-dose inotropic
support was defined when 7 mg $ kg1 $ min1 or greater of dopamine
or any dose of adrenaline was added.
Statistical Analysis
Descriptive statistics were summarized for categoric variables as
percentages and compared using the chi-square exact test. Univariate
logistic regressions were performed to identify preoperative independent
predictors for hospital mortality and MACE based on the preoperative
variables mentioned in Table 1. Multivariate logistic regression model
included those variables with a probability value of .05 or less for
association with at least 1 study end point.
To eliminate confounding bias due to unequal distribution of risk factors
among groups, propensity score was performed to generate a subset of
matched cases (statin therapy) and controls (no statin therapy) who had
the same distribution of covariates. SAS/STAT logistic procedure and a
SAS %GMATCH Macro program (SAS Institute Inc, Cary, NC) were
used to match cases to controls. Variables listed in Table 1 were used to
build a fully adjusted multivariable logistic regression model to compute
a propensity score for each patient. The cases were matched with controls
to create a 1-to-1 match.Matchingwas donewithout replacement, based on
caliper matching within a prespecified distance of a maximum of 0.2 of
the standard deviation of the logit of the propensity score. If more than
1 control matched equally to 1 case, the control was selected at random.
Comparisons between the 2 groups were performed by the chi-square
test to confirm that the 2 groups were successfully matched. The c statistic
was 0.89, indicating the good discriminatory power of the propensity
model. Hospital mortality and MACE were compared between the 2
matched groups by the 2-tailed McNemar test. Multi-way analysis of
variance with correction for serial measurements analyzed troponin I,
inotropic support, and postoperative creatinine levels. A Cox proportional
hazards model was constructed using the variables reported in Table 1 to
evaluate the effect of continuative statin therapy on 24-month survival
and MACE. All statistical analyses were performed with the SAS system,
version 9.1 (SAS Institute Inc) or SPSS version 13.0 for Windows
(SPSS Inc, Chicago, Ill).
RESULTS
All 2501 patients underwent CABG at a median of 38
months (interquartile range, 29-48) after a mean of 1.9
angioplasties by stenting. A total of 1211 patients
(48.4%) underwent operation with cardiopulmonary
bypass (CPB), and 1290 patients (51.6%) underwent
operation off-pump. In patients who underwent on-pump
CABG, mean CPB and mean aortic crossclamp times
were 83.5  25.2 minutes and 43.2  13.2 minutes,diovascular Surgery c Volume 148, Number 5 1877
TABLE 1. Main clinical and demographic characteristics
Statin group (1528) No statin group (973)
P valueNo. of patients % No. of patients %
Age 70 y 534 35 311 32 .06
Female sex 382 25 272 28 .1
BMI 275 18 205 21 .06
Hypertension 886 58 535 55 .1
Hypercholesterolemia 413 27 370 35 <.001
LDL cholesterol 120 mg/dL 395 26 358 37 <.001
Diabetes mellitus 581 38 331 34 .04
Peripheral vascular disease 244 16 116 12 .005
Respiratory disease 367 24 224 23 .6
Renal disease 137 9 78 8 .4
History of MI 718 47 399 41 .003
Ejection fraction 40% 245 16 146 15 .5
NYHA class III 580 38 341 35 .1
Logistic euroSCORE 5 458 30 253 26 .03
Multivessel coronary disease* 1008 66 613 63 .1
Left main disease 304 20 214 22 .2
Single previous PCI 993 64 678 69 .01
Multiple previous PCI 535 35 295 30 .01
Type of stent
Bare-metal 688 45 506 52 <.001
Drug-eluting 840 55 467 48 <.001
Indications for CABG
In-stent restenosis 504 33 294 30 .1
De novo stenosis 456 30 327 33 .6
Combined 539 35 332 35 .8
In-stent thrombosis 29 2 20 2 .9
3 grafts/patient 965 63 576 59 .1
Off-pump CABG 792 52 498 51 .8
On-pump CABG 736 48 475 49 .8
Aortic crossclamp time>80 min 271 18 145 15 .7
Therapy
Dual antiplatelet 1329 87 827 85 .1
Single antiplatelet (ASA) 199 13 146 15 .1
Insulin 81 5 50 5 .9
Oral hypoglycemic 506 33 287 29 .06
b-blockers 1100 72 671 69 .1
Calcium antagonists 488 32 301 31 .6
ACE inhibitors 352 23 204 21 .2
ACE, Angiotensin-converting enzyme; ASA, acetylsalicylic acid; BMI, body mass index; CABG, coronary artery bypass grafting; euroSCORE, European System for
Cardiac Operative Risk Evaluation; LDL, low-density lipoprotein; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
*Multivessel coronary disease was intended as 3-vessel or 2-vessel plus left main disease.
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(86.4  25.3 vs 84.7  30.1, P ¼ .07 and 43.8  12.3 vs
41.6  15.2, P ¼ .06). As a general rule, on-pump CABG
did not result in additional risks for hospital death or
MACE compared with off-pump CABG. However, on
multivariate analysis of the entire population of patients
who underwent on-pump operation, the risk of hospital
deaths and MACE was significantly increased in those
patients who had a prolonged aortic crossclamp time
(>80 minutes) (P ¼ .01 and P ¼ .01, respectively). In this
subpopulation, statin-treated patients had an odds of death
25% (95% CI, 0.25-0.95; P ¼ .03) and MACE 30%1878 The Journal of Thoracic and Cardiovascular Sur(95% CI, 0.12-0.8; P ¼ .03) lower than in statin-na€ıve
patients.
The number of conduits implanted was 4278 in the statin
group and 2530 in the no statin group. The average number
of grafts for patient was higher in the statin group (2.8 0.5
vs 2.6  0.6, P< .001). The index of completeness (the
number of grafts effectively performed on the number of
grafts intended at angiography) was similar (0.95 vs 0.94,
P¼ .8), as well as the use of the left internal thoracic artery
(1473/1528; 96% vs 946/973; 97%, P ¼ .1). Other arterial
conduits (right internal thoracic artery or radial artery) were
used in 65% of patients in the statin group (993/1528) andgery c November 2014
TABLE 2. Univariate and multivariate logistic regressions for hospital death
Characteristic
Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Age 70 y 2.5 (1.0-5.3) .02 2.4 (1.0-4.1) .04
Female sex 1.5 (0.6-3.5) .3
BMI 30 2.4 (0.9-6.5) .07
Hypertension 3.1 (1.5-6.2) <.001 2.2 (1.3-4.6) .008
Hypercholesterolemia 2.8 (1.2-6.7) .01 1.5 (0.6-3.4) .09
LDL cholesterol 120 mg/dL 1.7 (0.9-3.1) .05
Diabetes mellitus 3.1 (1.4-7.1) .003 2.8 (1.0-5.2) .02
Peripheral vascular disease 5.4 (1.8-15.3) .005 3.4 (1.4-9.7) .02
Respiratory disease 3.4 (1.0-10.8) .003 2.1 (0.7-7.2) .08
Renal disease 4.3 (1.1-15.5) .002 1.6 (0.8-11.1) .1
History of MI 4.3 (1.9-9.9) <.001 2.9 (1.5-6.1) .002
Ejection fraction 40% 4.2 (1.4-12.6) .004 2.1 (1.0-6.7) .02
NYHA class III 3.3 (1.3-8.1) .004 2.2 (0.8-5.5) .09
Logistic euroSCORE 5 2.8 (1.3-5.8) .003 1.3 (1.1-4.1) .01
Multivessel coronary disease* 2.3 (1.2-4.5) .008 2.0 (1.1-3.1) .01
Left main disease 50% 1.9 (0.9-4.5) .1
Single previous PCI 1.9 (0.8-4.4) .1
Multiple previous PCI 3.0 (1.3-6.3) .004 2.1 (1.1-4.4) .02
Type of stent
Bare-metal stent 2.1 (0.9-4.9) .07
Drug-eluting stent 2.5 (1.1-5.6) .01 1.8 (0.6-4.1) .1
Indications for CABG
In-stent restenosis 1.1 (0.2-5.5) .8
De novo stenosis 2.7 (0.9-8.5) .7
Combined 2.2 (0.8-6.5) .1
In-stent thrombosis 2.6 (0.7-9.5) .1
3 grafts/patients 1.8 (0.9-3.4) .05
Off-pump CABG 1.7 (0.7-4.2) .2
On-pump CABG 2.3 (1.0-4.9) .02 2.0 (0.8-3.2) .06
Aortic crossclamp time>80 min 2.4 (1.3-3.9) .008 2.1 (1.1-3.2) .01
Postoperative variables
High-dose inotropic support 2.4 (1.0-5.7) .03 1.8 (0.7-3.8) .09
Significant troponin I leakage 1.1 (0.4-2.9) .9
Therapy
Dual antiplatelet 2.0 (0.9-4.2) .05
Single antiplatelet (ASA) 2.5 (1.0-6.5) .03 1.9 (0.6-4.1) .08
Insulin 2.5 (1.1-5.9) .04 2.1 (0.7-4.2) .08
Oral hypoglycemic 1.2 (0.5-1.4) .8
b-blockers 1.1 (0.6-1.4) .7
Calcium antagonists 1.1 (0.5-1.2) .8
ACE inhibitors 1.4 (0.5-2.0) .9
ACE, Angiotensin-converting enzyme; ASA, acetylsalicylic acid; BMI, body mass index; CABG, coronary artery bypass grafting; CI, confidence interval; euroSCORE, European
System for Cardiac Operative Risk Evaluation; LDL, low-density lipoprotein;MI, myocardial infarction; NYHA, New York Heart Association;OR, odds ratio; PCI, percutaneous
coronary intervention. *Multivessel coronary disease was intended as 3-vessel or 2-vessel plus left main disease.
Mannacio et al Acquired Cardiovascular Disease
A
C
Din 59% of patients in the no statin group (574/973)
(P ¼ .003).
Total unadjusted hospital mortality was 2.3% (59/2501
patients). Mortality was lower in the statin group
(24/1528; 1.5% vs 35/973; 3.3%; P ¼ .001). Postoperative
MACE occurred more frequently in the no statin group
(79/1528; 5.1% vs 76/973; 7.8%, P ¼ .009). Univariate
and multivariate logistic regression analyses for hospital
deaths andMACE revealed several variables as independentThe Journal of Thoracic and Carpredictors for hospital deaths (Table 2) and MACE
(Table 3).
In agreement with the concept that preoperative statin
therapy protects renal function after coronary surgery,
mean serum creatinine levels were significantly increased
compared with preoperative values in the no statin
group (from 0.82  0.22 to 0.85  0.25, P ¼ .006)
than in the statin group (from 0.82  0.19 to 0.83  0.23,
P ¼ .2).diovascular Surgery c Volume 148, Number 5 1879
TABLE 3. Univariate and multivariate logistic regressions for major adverse cardiac events
Characteristic
Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Age 70 y 2.3 (1.4-3.7) <.001 1.8 (1.2-3.3) .01
Female sex 1.3 (0.8-2.2) .2
BMI 30 1.0 (0.9-1.9) .9
Hypertension 1.8 (1.2-2.8) .003 1.4 (1.0-2.1) .03
Hypercholesterolemia 1.6 (1.0-2.7) .04 1.2 (0.7-2.4) .07
LDL cholesterol 120 mg/dL 1.3 (0.7-2.4) .2 1.1 (1.0-2.2) .05
Diabetes mellitus 2.9 (1.8-4.8) <.001 2.2 (1.3-4.1) .004
Peripheral vascular disease 3.5 (2.0-6.1) <.001 2.8 (1.5-4.7) .002
Respiratory disease 1.4 (0.7-2.7) .4
Renal disease 1.6 (0.8-3.3) .1
History of MI 2.7 (1.6-4.5) <.001 1.9 (1.1-3.1) .008
Ejection fraction 40% 2.0 (1.1-3.6) .01 1.8 (1.0-3.1) .04
NYHA class III 1.7 (1.0-2.8) .02 1.4 (0.8-2.1) .1
Logistic euroSCORE 5 2.1 (1.3-3.4) <.001 1..9 (1.1-3.0) .007
Multivessel coronary disease* 1.8 (1.2-2.6) .001 1.4 (1.0-2.3) .03
Left main disease 50% 1.6 (0.9-2.6) .05
Single previous PCI 1.4 (0.7-2.7) .3
Multiple previous PCI 1.9 (1.2-2.9) .001 1.6 (0.7-2.4) .08
Type of stent
Bare-metal stent 1.4 (0.9-2.2) .1
Drug-eluting stent 1.6 (1.0-2.7) .04 1.4 (0.6-2.1) .1
Indications for CABG
In-stent restenosis 1.9 (1.0-3.7) .03 1.2 (0.5-2.7) .1
De novo stenosis 1.7 (0.9-3.4) .1
Combined 1.3 (0.7-2.5) .5
In-stent thrombosis 1.4 (0.6-3.4) .4
3 grafts/patient 1.4 (1.0-2.1) .04 1.3 (0.7-1.8) .1
Off-pump CABG 1.4 (0.8-2.5) .2
On-pump CABG 1.6 (1.0-2.4) .03 1.4 (07-2.1) .09
Aortic crossclamp time>80 min 1.7 (1.1-2.6) .004 1.4 (1.0-2.1) .01
Postoperative variables
High-dose inotropic support 1.3 (0.7-2.5) .3
Significant troponin I leakage 2.1 (1.2-3.8) .004 1.8 (1.1-3.3) .009
Therapy
Dual antiplatelet 1.2 (0.7-2.2) .3
Single antiplatelet (ASA) 1.7 (1.0-2.8) .03 1.4 (0.7-2.1) .09
Insulin 2.2 (1.3-3.8) .004 1.9 (1.2-3.1) .01
Oral hypoglycemic 1.2 (0.6-2.8) .2
b-blockers 1.1 (0.5-2.5) .2
Calcium antagonists 1.4 (0.8-2.6) .3
ACE inhibitors 1.6 (0.7-2.9) .2
ACE, Angiotensin-converting enzyme; ASA, acetylsalicylic acid; BMI, body mass index; CABG, coronary artery bypass grafting; CI, confidence interval; euroSCORE, European
System for Cardiac Operative Risk Evaluation; LDL, low-density lipoprotein;MI, myocardial infarction; NYHA, New York Heart Association;OR, odds ratio; PCI, percutaneous
coronary intervention. *Multivessel coronary disease was intended as 3-vessel or 2-vessel plus left main disease.
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treated by PCI for the left anterior descending artery and
patients who had been treated for a coronary artery other
than the left anterior descending artery showed no
differences in hospital mortality (P ¼ .7) and MACE
(P ¼ .4). Likewise, patients with a history of single PCI
had no significant differences between groups in terms of
hospital deaths (12/993; 1.2% in the statin group vs
10/678; 1.4% in the no statin group, P ¼ .8) or MACE1880 The Journal of Thoracic and Cardiovascular Sur(33/993; 3.3% in the statin group vs 31/678; 4.5% in the
no statin group, P¼ .2). By contrast, a significant reduction
of hospital deaths and MACE occurred in the statin group
when subgroups of patients with a history of multiple PCI
were compared (12/535; 2.2% vs 25/295; 8.4%, P<.001
and 46/535; 8.4% vs 45/295; 15.2%, P ¼ .004).
A high dose of inotropic support postoperatively was
required by 152 patients (9.9%) in the statin group versus
144 patients (14.7%) in the no statin group (P< .001).gery c November 2014
TABLE 4. Main clinical and demographic patient characteristics in subgroups matched on propensity score
Statin group (931) No statin group (931)
P valueNo. of patients % No. of patients %
Age 70 y 303 32 292 31 .6
Female sex 251 27 257 27 .8
BMI 199 21 191 20 .6
Hypertension 538 58 521 56 .4
Hypercholesterolemia 371 40 361 39 .6
LDL cholesterol 120 mg/dL 348 37 351 38 .07
Diabetes mellitus 335 36 331 35 .9
Peripheral vascular disease 123 13 113 12 .8
Respiratory disease 220 24 222 24 .9
Renal disease 85 9 78 8 .6
History of MI 415 44 398 42 .4
Ejection fraction 40% 141 15 135 14 .8
NYHA class III 341 36 331 35 .6
Logistic euroSCORE 5 245 26 239 25 .8
Multivessel coronary disease* 615 66 601 64 .5
Left main disease 201 22 203 22 .9
Single previous PCI 644 69 650 70 .8
Multiple previous PCI 287 31 281 30 .8
Type of stent
Bare-metal 469 50 483 52 .5
Drug-eluting 462 50 448 48 .5
Indications for CABG
In-stent restenosis 279 30 285 30 .9
De novo stenosis 310 33 317 34 .7
Combined 327 35 312 34 .7
In-stent thrombosis 15 2 17 2 .9
3 grafts/patient 585 63 550 59 .6
Off-pump CABG 483 52 473 51 .6
On-pump CABG 448 48 458 49 .6
Aortic crossclamp time>80 min 142 15 137 14 .8
Therapy
Dual antiplatelet
Single antiplatelet (ASA) 121 13 137 15 .3
Insulin 33 3 36 3 .9
Oral hypoglycemic 288 31 270 29 .4
b-blockers 670 72 670 69 .9
Calcium antagonists 281 30 288 31 .7
ACE inhibitors 216 23 203 22 .5
ACE, Angiotensin-converting enzyme; ASA, acetylsalicylic acid; BMI, body mass index; CABG, coronary artery bypass grafting; euroSCORE, European System for
Cardiac Operative Risk Evaluation; LDL, low-density lipoprotein; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
*Multivessel coronary disease was intended as 3-vessel or 2-vessel plus left main disease.
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occurred in the no statin group (61.9% vs 37.8%,
P< .001). Mean postoperative peak value of troponin I
was lower in the statin group (0.21  0.18 ng/mL vs 0.42
 0.38 ng/mL; P<.001). Troponin I levels peaked at 12
hours after the operation in the statin group and at 8 hours
in the no statin group.
After propensity score matching, 931 cases were
successfully 1:1 matched with 931 corresponding controls
(Table 4). After matching, the average number of grafts
for patients was similar in both groups (2.72  0.8 vs
2.66  0.5, P ¼ .05), as well as the number of leftThe Journal of Thoracic and Carthoracic arteries implanted (914 in the statin group vs
917 in the no statin group, P ¼ 1). Other arterial conduits
(right internal thoracic artery or radial artery) were used
in 63% of the statin group (591/931) and in 59% of
the no statin group (550/931) (P ¼ .06). Postoperative
hospitalization was significantly lower in the statin group
(10.2  2.9 days vs 9.2  2.9 days, P< .001). Hospital
mortality was 1.9% (18 of 931) in the statin group versus
3.7% (35/931) in the no statin group (P ¼ .02), and the
MACE rate was 5.5% (52/931) versus 9.1% (85/931),
respectively (P ¼ .03). The McNemar test for paired
proportion confirmed significant differences in hospitaldiovascular Surgery c Volume 148, Number 5 1881
TABLE 5. Two-year mortality and major adverse cardiac events in
propensity score matched patients analyzed by Cox regression model
Variables P value Exp 95% CI
Mortality
Ejection fraction 0.40 .004 1.7 1.3-2.9
Multiple previous PCI <.001 2.4 1.5-3.6
Multivessel coronary disease* .006 2.1 1.7-2.6
Logistic euroSCORE 5 .004 2.3 1.8-3.4
Perioperative troponin I leakage <.001 3.1 2.1-3.8
No statin therapy before CABG .002 3.0 2.0-3.6
MACE
Female sex .02 1.8 1.2-3.1
Diabetes mellitus .02 1.9 1.3-3.5
Peripheral vascular disease .009 2.1 1.4-4.1
Multiple previous PCI <.001 2.7 1.9-3.9
Logistic euroSCORE 5 <.001 2.7 1.8-3.9
Multivessel coronary disease* .002 2.4 2.1-3.5
Perioperative troponin I leakage <.001 3.1 2.1-4.5
No statin therapy before CABG <.001 3.4 2.2-4.6
Single antiplatelet (ASA) .008 2.1 1.4-3.9
Variables tested: demographic and clinical variables reported in Table 1.
ASA, Acetylsalicylic acid; CABG, coronary artery bypass grafting; CI, confidence
interval; euroSCORE, European System for Cardiac Operative Risk Evaluation;
MACE, major adverse cardiac events; PCI, percutaneous coronary intervention.
*Multivessel coronary disease was intended as 3-vessel or 2-vessel plus left main
disease.
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[CI], 1.1-3.5; P ¼ .001) and MACE (OR, 1.6; 95% CI,
1.1-2.3; P ¼ .006). Conditional logistic regression
analysis confirmed that continuative statin therapy after
previous PCI was significantly associated with reduced
risk for hospital mortality (OR, 0.27; 95% CI, 0.12-0.
57; P ¼ .004) and MACE (OR, 0.31; 95% CI,
0.18-0.78; P ¼ .003).
Two-year follow-up was 95% complete for mortality and
88% complete for MACE in the propensity score–matched
population. Cardiac deaths and MACE at 2 years were
significantly lower in the statin group than in the no statin
group (3.4% vs 5.3%, P ¼ .04 and 5.5% vs 10.4%,
P ¼ .006). Conditional logistic regression analysis
confirmed that continuative statin therapy after previous
PCI was significantly associated with reduced risk for
2-year mortality (OR, 0.6; 95% CI, 0.36-0.96; P ¼ .04)
and MACE (OR, 0.5; 95% CI, 0.34-0.76; P ¼ .006). More-
over, all demographic and clinical variables listed in Table 1
were analyzed by Cox regression model for their effect on
2-year survival and MACE (Table 5).
DISCUSSION
Our results demonstrate that patients with a history of
PCI with stenting who were treated by continuative statin
therapy before elective primary CABG had a significantly
lower risk of operative mortality and MACE and better
survival and freedom from MACE at 2 years follow-up
compared with untreated patients.1882 The Journal of Thoracic and Cardiovascular SurAfter risk adjustment in a multivariate regression model,
age 70 years or more, female sex, ejection fraction 0.40 or
less, hypertension, diabetes mellitus, previous MI, 3-vessel
or 2-vessel plus left main disease, logistic European System
for Cardiac Operative Risk Evaluation 5 or greater, multiple
previous PCI, and aortic crossclamp time 80 minutes or
more in patients undergoing operation with CPB were
independent preoperative markers of deaths and complica-
tions. By contrast, the type of stent implanted did not result
in significant detrimental effects on hospital mortality and
MACE. Of note, perioperative leakage of troponin I was
significantly lower in statin-treated patients and was an
independent predictor of hospital MACE and 2-year deaths
and MACE. This finding is consistent with data from
recent literature reporting that an absolute reduction of
perioperative troponin I release would translate into a
reduction of surgical and overall risk after CABG surgery.22
After the statin-treated and untreated patients were
balanced by propensity score matching, the benefits
conferred by continuative statin therapy on both mortality
and MACE were confirmed by an approximately 2-fold
risk reduction.
The exact mechanisms underlying these results are
unclear and cannot be elucidated from this study. It is likely
that statin pleiotropic properties could attenuate the chronic
inflammation and focal trauma secondary to PCI, both of
which play an important role in the evolution of coronary
artery disease.23-26 This hypothesis is supported by Laufs
and coworkers,27 who demonstrated that statins enhance
endothelial nitric oxide (NO) production by directly
upregulating endothelial cell NO synthase expression and
activity. Thus, by reversing the inhibitory effects of
oxidized low-density lipoprotein on endothelial cell NO
synthase expression, statins may increase the availability
of endothelium-derived NO, which is known to provide
the stabilization of the endothelial function and the
optimization of local flow.27 Finally, it is noteworthy
that patients in the statin group displayed a slight, but
statistically significant prolonged interval of time from
PCI to CABG surgery.
Study Limitations
The retrospective nature of the analysis represents the
main limitation of this study. Nevertheless, despite the use
of propensity scoring and multivariate regression models,
immeasurable or unknown factors of bias may still exist.
The study also could be limited because of the lack of
available cardiac catheterization data at the time of PCI,
which hampered the evaluation of coronary lesions and
the completeness of percutaneous revascularization, both
of which are important determinants of outcome after
PCI. Moreover, we could not comment on whether
the type of stent used had some impact on outcome
because different devices with different characteristicsgery c November 2014
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Dand indications were implanted in patients over time.
Finally, we cannot discuss the specific effectiveness of
each statin because different types of statins were used at
variable doses and the types of statins were changed in a
number of patients between PCI and subsequent CABG.
CONCLUSIONS
Our results demonstrate a substantial improvement in
outcome for statin-treated patients who required subsequent
CABG surgery after PCI. This study may provide further
evidence in the ongoing discussion of beneficial effects of
statin and supports a more extensive use of statins, not
only in hyperlipidemic patients, as a long-term treatment
after PCI. It is regrettable that although statins are indicated
by current guidelines, they are underused in daily practice
and long-term adherence to drug regimens is generally
poor. Our results suggest careful statin treatment after PCI
to fully benefit from the potential of these agents in terms
of delayed necessity of repeat surgical revascularization
and better outcome when surgical revascularization is
required.
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